Skip to main content

Table 2 Incidence of Treatment-Related AEs Reported by ≥1% of Patients

From: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study

  MF-DPI 400 μg QD PM
(n = 611)
MF-DPI 200 μg BID
(n = 622)
Patients reporting any AE, n (%) 85 (14) 109 (18)
   Headache 10 (2) 12 (2)
   Dysphonia 3 (<1) 9 (1)
   Mouth dry 12 (2) 11 (2)
   Mouth ulceration 5 (1) 1 (<1)
   Candidiasis, oral 9 (1) 16(3)
   Pharyngitis 16 (3) 15 (2)
   Upper respiratory tract infection 5 (1) 0
   Cough 2 (<1) 6 (1)
   Hoarseness 4 (1) 5 (1)
   Throat dry 11 (2) 3 (<1)
   Rash 0 4 (1)
  1. AE = adverse event; BID = twice-daily; MF-DPI = mometasone furoate administered via a dry powder inhaler; QD PM = once-daily in the evening.